See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is used to improve glycemic control in adults with type 2 diabetes. It is available as a prefilled pen for injection and is typically administered once a week.

According to the drug's prescribing information, Ozempic can cause nausea, vomiting, and decreased appetite, which may lead to a reduction in food intake. However, it is not indicated for weight loss and should not be used as a primary means of controlling food intake or managing obesity.

It is important to note that Ozempic should be used in conjunction with a healthy diet and exercise program, as directed by a healthcare professional. Patients should not make any changes to their diet or physical activity levels without first consulting their healthcare provider.

In summary, Ozempic can influence how much a person eats due to its side effects of nausea, vomiting, and decreased appetite, but it is not intended for weight loss and should be used as directed by a healthcare professional.

Sources:

1. [Ozempic (semaglutide) injection, for subcutaneous use [prescribing information]. Novo Nordisk Inc. 2021.](https://www.novo-pi.com/ozempic.pdf)
2. [DrugPatentWatch.com - Ozempic (semaglutide) - Patent, Legal, and Regulatory Information.](https://www.drugpatentwatch.com/drugs/ozempic)